Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX301 in Advanced Solid Tumors and Lymphoma
NCT05390528Phase 2Unknown
- Sponsor
- Henlius
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hlx301 in solid tumor (advanced stage), metastatic solid tumor, lymphoma, non-small cell lung cancer (NSCLC), gastric adenocarcinoma, sponsored by Henlius. Status: unknown.
02
Drugs
hlx301
03
Conditions
solid tumor (advanced stage)metastatic solid tumorlymphomanon-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05390528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390528.